Table 2.

Pembrolizumab and Mitotane Therapy Details

Patient ID	1	2	3	4	5	6
Time from diagnosis until starting pembrolizumab, mo	95	7	5	76	58	38
Cycles of pembrolizumab received until March 2019	27	42	25	11	35	25
Months on pembrolizumab until March 2019	18	31	19	8	26	16
Number of pembrolizumab cycle delays	1	3	1	None	1	None
Discontinuation of pembrolizumab because of side effects	Yes	No	No	Yes	No	No
Duration of mitotane therapy prior to starting pembrolizumab, mo	46	3	5	10	56	37
Mean mitotane level during treatment with pembrolizumab, μg/mL	18.2	11.3	11.2	2.6	13.3	16.6
Range of mitotane levels during treatment with pembrolizumab, μg/mL	15.1–25.2	9.8–12.1	2.9–25.6	0–6	10.0–15.0	14.9–17.6
Time spent off mitotane while on pembrolizumab, mo	0	0	2	4	2	0
Total duration of mitotane therapy, mo	62	26	22	14	72	45